Pet imaging for gene & cell therapy

Sara A. Collins, Kei Hiraoka, Akihito Inagaki, Noriyuki Kasahara, Mark Tangney

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

As the interest in gene therapy increases, the development of an efficient and reliable means to monitor gene delivery and expression in patients is becoming more important. An ideal imaging modality would be non-invasive, allowing for repeated imaging, thus validating stages subsequent to vector administration and allowing for the improvement of clinical protocols. Positron Emission Tomography (PET) has been employed for some time in clinical imaging and has in more recent years been adapted to enable imaging in small animal models, including gene therapy models for a range of diseases. PET imaging is based on the detection of trace quantities of positron-emitting molecular probe within cells post-administration, permitting imaging of target molecules in vivo, and numerous tracers have been developed for a wide range of applications, including imaging of reporter gene activity. Use of radiolabelled substrates that interact with specific transgene proteins, has identified a number of reporter genes that are suitable for imaging vector mediated gene delivery and expression in both pre-clinical and clinical situations. These reporter genes enable non-invasive analysis of the location, level and kinetics of transgene activity. Among the various imaging modalities in existence, the PET approach displays arguably the optimum characteristics in terms of sensitivity and quantitation for in vivo gene expression measurements. Given the existing availability of PET scanning equipment and expertise in hospitals, this imaging modality represents the most clinically applicable means of analysing gene therapy in patients. This review outlines the principles of PET imaging in the context of gene and cell therapy at both pre-clinical and clinical levels, comparing PET with other relevant modalities, and describes the progress to date in this field.

Original languageEnglish (US)
Pages (from-to)20-32
Number of pages13
JournalCurrent Gene Therapy
Volume12
Issue number1
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

Pets
Cell- and Tissue-Based Therapy
Positron-Emission Tomography
Genetic Therapy
Reporter Genes
Genes
Transgenes
Gene Expression
Molecular Probes
Clinical Protocols
Animal Models
Electrons
Equipment and Supplies
Proteins

Keywords

  • Cancer
  • Clinical imaging
  • HSV-TK
  • Molecular imaging
  • Nuclear medicine
  • Positron emission tomography
  • Reporter
  • Vector

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery

Cite this

Collins, S. A., Hiraoka, K., Inagaki, A., Kasahara, N., & Tangney, M. (2012). Pet imaging for gene & cell therapy. Current Gene Therapy, 12(1), 20-32.

Pet imaging for gene & cell therapy. / Collins, Sara A.; Hiraoka, Kei; Inagaki, Akihito; Kasahara, Noriyuki; Tangney, Mark.

In: Current Gene Therapy, Vol. 12, No. 1, 02.2012, p. 20-32.

Research output: Contribution to journalArticle

Collins, SA, Hiraoka, K, Inagaki, A, Kasahara, N & Tangney, M 2012, 'Pet imaging for gene & cell therapy', Current Gene Therapy, vol. 12, no. 1, pp. 20-32.
Collins SA, Hiraoka K, Inagaki A, Kasahara N, Tangney M. Pet imaging for gene & cell therapy. Current Gene Therapy. 2012 Feb;12(1):20-32.
Collins, Sara A. ; Hiraoka, Kei ; Inagaki, Akihito ; Kasahara, Noriyuki ; Tangney, Mark. / Pet imaging for gene & cell therapy. In: Current Gene Therapy. 2012 ; Vol. 12, No. 1. pp. 20-32.
@article{504bc359da414138ab67e6f527d7dc36,
title = "Pet imaging for gene & cell therapy",
abstract = "As the interest in gene therapy increases, the development of an efficient and reliable means to monitor gene delivery and expression in patients is becoming more important. An ideal imaging modality would be non-invasive, allowing for repeated imaging, thus validating stages subsequent to vector administration and allowing for the improvement of clinical protocols. Positron Emission Tomography (PET) has been employed for some time in clinical imaging and has in more recent years been adapted to enable imaging in small animal models, including gene therapy models for a range of diseases. PET imaging is based on the detection of trace quantities of positron-emitting molecular probe within cells post-administration, permitting imaging of target molecules in vivo, and numerous tracers have been developed for a wide range of applications, including imaging of reporter gene activity. Use of radiolabelled substrates that interact with specific transgene proteins, has identified a number of reporter genes that are suitable for imaging vector mediated gene delivery and expression in both pre-clinical and clinical situations. These reporter genes enable non-invasive analysis of the location, level and kinetics of transgene activity. Among the various imaging modalities in existence, the PET approach displays arguably the optimum characteristics in terms of sensitivity and quantitation for in vivo gene expression measurements. Given the existing availability of PET scanning equipment and expertise in hospitals, this imaging modality represents the most clinically applicable means of analysing gene therapy in patients. This review outlines the principles of PET imaging in the context of gene and cell therapy at both pre-clinical and clinical levels, comparing PET with other relevant modalities, and describes the progress to date in this field.",
keywords = "Cancer, Clinical imaging, HSV-TK, Molecular imaging, Nuclear medicine, Positron emission tomography, Reporter, Vector",
author = "Collins, {Sara A.} and Kei Hiraoka and Akihito Inagaki and Noriyuki Kasahara and Mark Tangney",
year = "2012",
month = "2",
language = "English (US)",
volume = "12",
pages = "20--32",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Pet imaging for gene & cell therapy

AU - Collins, Sara A.

AU - Hiraoka, Kei

AU - Inagaki, Akihito

AU - Kasahara, Noriyuki

AU - Tangney, Mark

PY - 2012/2

Y1 - 2012/2

N2 - As the interest in gene therapy increases, the development of an efficient and reliable means to monitor gene delivery and expression in patients is becoming more important. An ideal imaging modality would be non-invasive, allowing for repeated imaging, thus validating stages subsequent to vector administration and allowing for the improvement of clinical protocols. Positron Emission Tomography (PET) has been employed for some time in clinical imaging and has in more recent years been adapted to enable imaging in small animal models, including gene therapy models for a range of diseases. PET imaging is based on the detection of trace quantities of positron-emitting molecular probe within cells post-administration, permitting imaging of target molecules in vivo, and numerous tracers have been developed for a wide range of applications, including imaging of reporter gene activity. Use of radiolabelled substrates that interact with specific transgene proteins, has identified a number of reporter genes that are suitable for imaging vector mediated gene delivery and expression in both pre-clinical and clinical situations. These reporter genes enable non-invasive analysis of the location, level and kinetics of transgene activity. Among the various imaging modalities in existence, the PET approach displays arguably the optimum characteristics in terms of sensitivity and quantitation for in vivo gene expression measurements. Given the existing availability of PET scanning equipment and expertise in hospitals, this imaging modality represents the most clinically applicable means of analysing gene therapy in patients. This review outlines the principles of PET imaging in the context of gene and cell therapy at both pre-clinical and clinical levels, comparing PET with other relevant modalities, and describes the progress to date in this field.

AB - As the interest in gene therapy increases, the development of an efficient and reliable means to monitor gene delivery and expression in patients is becoming more important. An ideal imaging modality would be non-invasive, allowing for repeated imaging, thus validating stages subsequent to vector administration and allowing for the improvement of clinical protocols. Positron Emission Tomography (PET) has been employed for some time in clinical imaging and has in more recent years been adapted to enable imaging in small animal models, including gene therapy models for a range of diseases. PET imaging is based on the detection of trace quantities of positron-emitting molecular probe within cells post-administration, permitting imaging of target molecules in vivo, and numerous tracers have been developed for a wide range of applications, including imaging of reporter gene activity. Use of radiolabelled substrates that interact with specific transgene proteins, has identified a number of reporter genes that are suitable for imaging vector mediated gene delivery and expression in both pre-clinical and clinical situations. These reporter genes enable non-invasive analysis of the location, level and kinetics of transgene activity. Among the various imaging modalities in existence, the PET approach displays arguably the optimum characteristics in terms of sensitivity and quantitation for in vivo gene expression measurements. Given the existing availability of PET scanning equipment and expertise in hospitals, this imaging modality represents the most clinically applicable means of analysing gene therapy in patients. This review outlines the principles of PET imaging in the context of gene and cell therapy at both pre-clinical and clinical levels, comparing PET with other relevant modalities, and describes the progress to date in this field.

KW - Cancer

KW - Clinical imaging

KW - HSV-TK

KW - Molecular imaging

KW - Nuclear medicine

KW - Positron emission tomography

KW - Reporter

KW - Vector

UR - http://www.scopus.com/inward/record.url?scp=84858319398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858319398&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 20

EP - 32

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 1

ER -